Moreover, recent studies have confirmed that dasatinib can switch off the cytokine release to reduce the risk of CRS by inhibiting the SRC family kinase lymphocyte-specific protein tyrosine kinase (LCK) (Mestermann et al., 2019; Leclercq et al., 2021). The gene discussed is LCK; the disease is congenital rubella syndrome.